Logo image of APDN

APPLIED DNA SCIENCES INC (APDN) Stock Fundamental Analysis

NASDAQ:APDN - Nasdaq - US03815U4094 - Common Stock

0.18  -0.01 (-5.96%)

Premarket: 0.1767 0 (-1.83%)

Fundamental Rating

2

Overall APDN gets a fundamental rating of 2 out of 10. We evaluated APDN against 56 industry peers in the Life Sciences Tools & Services industry. The financial health of APDN is average, but there are quite some concerns on its profitability. APDN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APDN has reported negative net income.
In the past year APDN has reported a negative cash flow from operations.
In the past 5 years APDN always reported negative net income.
In the past 5 years APDN always reported negative operating cash flow.
APDN Yearly Net Income VS EBIT VS OCF VS FCFAPDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

APDN has a Return On Assets of -56.50%. This is amonst the worse of the industry: APDN underperforms 92.86% of its industry peers.
APDN has a Return On Equity of -79.03%. This is in the lower half of the industry: APDN underperforms 76.79% of its industry peers.
Industry RankSector Rank
ROA -56.5%
ROE -79.03%
ROIC N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
APDN Yearly ROA, ROE, ROICAPDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 29.64%, APDN is doing worse than 73.21% of the companies in the same industry.
In the last couple of years the Gross Margin of APDN has declined.
The Profit Margin and Operating Margin are not available for APDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 29.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
APDN Yearly Profit, Operating, Gross MarginsAPDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

APDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, APDN has more shares outstanding
Compared to 5 years ago, APDN has more shares outstanding
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APDN Yearly Shares OutstandingAPDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
APDN Yearly Total Debt VS Total AssetsAPDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -35.17, we must say that APDN is in the distress zone and has some risk of bankruptcy.
APDN has a Altman-Z score of -35.17. This is amonst the worse of the industry: APDN underperforms 98.21% of its industry peers.
APDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -35.17
ROIC/WACCN/A
WACC10.63%
APDN Yearly LT Debt VS Equity VS FCFAPDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

A Current Ratio of 3.36 indicates that APDN has no problem at all paying its short term obligations.
The Current ratio of APDN (3.36) is comparable to the rest of the industry.
A Quick Ratio of 3.17 indicates that APDN has no problem at all paying its short term obligations.
APDN has a better Quick ratio (3.17) than 60.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 3.17
APDN Yearly Current Assets VS Current LiabilitesAPDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.60% over the past year.
The Revenue for APDN has decreased by -74.33% in the past year. This is quite bad
The Revenue has been decreasing by -8.63% on average over the past years.
EPS 1Y (TTM)53.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.85%
Revenue 1Y (TTM)-74.33%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%3.85%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y84.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year48.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APDN Yearly Revenue VS EstimatesAPDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
APDN Yearly EPS VS EstimatesAPDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

APDN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for APDN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APDN Price Earnings VS Forward Price EarningsAPDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APDN Per share dataAPDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

APDN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED DNA SCIENCES INC

NASDAQ:APDN (1/21/2025, 8:00:00 PM)

Premarket: 0.1767 0 (-1.83%)

0.18

-0.01 (-5.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)12-17 2024-12-17/amc
Earnings (Next)02-13 2025-02-13
Inst Owners11.86%
Inst Owner Change0%
Ins Owners0.95%
Ins Owner Change0%
Market Cap9.41M
Analysts43.33
Price Target1.53 (750%)
Short Float %12.1%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)119.69%
Min EPS beat(2)7.73%
Max EPS beat(2)231.65%
EPS beat(4)3
Avg EPS beat(4)73.81%
Min EPS beat(4)-15.69%
Max EPS beat(4)231.65%
EPS beat(8)6
Avg EPS beat(8)53.23%
EPS beat(12)9
Avg EPS beat(12)40.58%
EPS beat(16)9
Avg EPS beat(16)19.02%
Revenue beat(2)0
Avg Revenue beat(2)-19.64%
Min Revenue beat(2)-27.61%
Max Revenue beat(2)-11.67%
Revenue beat(4)1
Avg Revenue beat(4)-7.71%
Min Revenue beat(4)-27.61%
Max Revenue beat(4)12.59%
Revenue beat(8)4
Avg Revenue beat(8)-5.34%
Revenue beat(12)7
Avg Revenue beat(12)-0.43%
Revenue beat(16)10
Avg Revenue beat(16)-0.31%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.74
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.46
EV/EBITDA N/A
EPS(TTM)-6.96
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.07
BVpS0.17
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.5%
ROE -79.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 29.64%
FCFM N/A
ROA(3y)-55.66%
ROA(5y)-76.19%
ROE(3y)-114.94%
ROE(5y)-140.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.42%
GM growth 5Y-18.75%
F-Score3
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.57%
Cap/Sales 11.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 3.17
Altman-Z -35.17
F-Score3
WACC10.63%
ROIC/WACCN/A
Cap/Depr(3y)60.08%
Cap/Depr(5y)170.88%
Cap/Sales(3y)7.71%
Cap/Sales(5y)21.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.85%
EPS Next Y84.69%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-74.33%
Revenue growth 3Y-27.56%
Revenue growth 5Y-8.63%
Sales Q2Q%3.85%
Revenue Next Year48.01%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-91.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-120.52%
OCF growth 3YN/A
OCF growth 5YN/A